文献速递眼底病与葡萄膜炎神经眼科

多组织组学揭示酰基肉碱积累是糖尿病微血管病变共享代谢标志物

Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究在链脲佐菌素诱导的糖尿病小鼠中对视网膜、血浆和肾脏进行多组织代谢组学分析,发现一种保守的全身性脂毒性特征,并构建了由游离肉碱和两种长链酰基肉碱组成的预测性血浆面板。临床转录组学和孟德尔随机化分析确定SLC22A5和CPT2轴同步下调是该脂质失衡的因果遗传特征,提示循环肉碱/酰基肉碱特征可作为微血管风险的非侵入性指标。

要点

  • 糖尿病视网膜病变与糖尿病肾病共享全身性酰基肉碱代谢紊乱。
  • 血浆游离肉碱和两种长链酰基肉碱组成的面板可预测微血管风险。
  • SLC22A5-CPT2轴下调是脂质失衡的因果遗传特征,为潜在治疗靶点。

核心结论

  • 糖尿病视网膜病变和糖尿病肾病均与酰基肉碱代谢的全身性紊乱相关。
  • 循环肉碱/酰基肉碱特征可能作为微血管风险的非侵入性指标。
  • SLC22A5-CPT2轴代表潜在治疗靶点。

研究设计与样本

  • 在链脲佐菌素诱导的糖尿病小鼠中对视网膜、血浆和肾脏进行多组织代谢组学分析。
  • 利用公开的人类糖尿病视网膜病变和糖尿病肾病转录组数据集支持临床相关性。
  • 采用eQTLGen和全基因组关联研究汇总统计进行两样本孟德尔随机化评估因果关系。
  • 进行单细胞计算机扰动分析预测器官特异性功能后果。

主要发现

  • 跨器官代谢组学分析识别出一种保守的全身性脂毒性特征。
  • 构建了由游离肉碱和两种长链酰基肉碱组成的预测性血浆面板。
  • 临床转录组学和孟德尔随机化分析确定SLC22A5和CPT2轴同步下调是该脂质失衡的因果遗传特征。
  • 计算机单细胞分析显示该共享代谢紊乱在各组织中诱导不同的转录反应,提示组织特异性分子反应可能促成器官特异性微血管功能障碍。

临床怎么用

  • 循环肉碱/酰基肉碱特征有望作为评估糖尿病微血管风险的非侵入性指标。
  • SLC22A5-CPT2轴可作为糖尿病微血管病变的潜在治疗靶点。

局限性

  • 研究基于链脲佐菌素诱导的糖尿病小鼠模型,人类临床相关性仅通过公共转录组数据集和孟德尔随机化分析支持。
  • 单细胞分析为计算机扰动预测,需实验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Diabetic retinopathy (DR) is often recognized as a marker of systemic microvascular disease, but the metabolic links to other complications, such as diabetic nephropathy (DN), remain unclear. We aimed to identify systemic metabolic signatures shared by DR and DN and investigate their potential causal mechanisms. METHODS: Multi-tissue metabolomic profiling of the retina, plasma, and kidney was performed in streptozotocin-induced diabetic mice. Clinical relevance was supported by public human DR and DN transcriptomic datasets. Causal relationships were assessed by two-sample Mendelian randomization (MR) using eQTLGen and genome-wide association study (GWAS) summary statistics. Single-cell in silico perturbation analysis was performed to predict organ-specific functional consequences. RESULTS: Cross-organ metabolomic profiling identified a conserved systemic lipotoxic signature, yielding a predictive plasma panel comprised of free carnitine and two long-chain acylcarnitines. Clinical transcriptomics and MR analyses pinpointed the synchronous downregulation of the SLC22A5 and CPT2 axis as a causal genetic signature of this lipid imbalance. Furthermore, in silico single-cell analyses revealed that this shared metabolic disturbance induced distinct transcriptional responses across tissues, suggesting tissue-specific molecular responses that may contribute to organ-specific microvascular dysfunction. CONCLUSIONS: Both DR and DN are associated with systemic disruption of acylcarnitine metabolism. A circulating carnitine/acylcarnitine signature may serve as a non-invasive indicator of microvascular risk, and the SLC22A5-CPT2 axis represents a potential therapeutic target.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Liu Q, Liu Y, Yang X, et al. Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation. Invest Ophthalmol Vis Sci. 2026. PMID: 42747258. doi:10.1167/iovs.67.11.31

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。